Sandra Susanibar-Adaniya

20PUBLICATIONS
129CO-AUTHORS
Early English languagesCancer therapy (excl. chemotherapy and radiation therapy)Applied immunology (incl. antibody engineering, xenotransplantation and t-cell therapies)Regenerative medicine (incl. stem cells)Molecular targets
Featured researcher

Get your video featured.

JoVEPublish with JoVE
Journal

Publications (20)

|Aug 05, 2026
Evaluating Artificial Intelligence Translation Tools for Language Equivalence of Oncology-Informed Consent Forms From English to Spanish.

|Jan 15, 2026
CD4+ T cells mediate CAR-T cell-associated immune-related adverse events after BCMA CAR-T cell therapy.

Matthew Ho, Luca Paruzzo, Julia Han Noll

|Nov 28, 2025
The impact of extramedullary and paraskeletal plasmacytomas on treatment outcomes in multiple myeloma treated with teclistamab: U.S. Myeloma Immunotherapy Consortium real-world experience.

Aimaz Afrough, Danai Dima, Beatrice Razzo

|Jul 09, 2025
Real-World Experience with Teclistamab for Relapsed/Refractory Multiple Myeloma from the US Myeloma Immunotherapy Consortium.

Beatrice M Razzo, Shonali Midha, Andrew J Portuguese

|Jun 25, 2025
Outcomes of teclistamab in patients with relapsed/refractory multiple myeloma with prior exposure to BCMA-directed therapy: a multicenter study from the U.S. Multiple Myeloma Immunotherapy Consortium.

Danai Dima, Mariola A Vazquez-Martinez, James A Davis

|May 09, 2025
Outcomes of elderly patients with relapsed refractory multiple myeloma (RRMM) treated with teclistamab: a multicenter study from the U.S. Multiple Myeloma Immunotherapy Consortium.

Oren Pasvolsky, Danai Dima, Lei Feng

Pageof 4

Frequent Collaborators

14 joint publications

Alfred L Garfall

10 joint publications

Adam D Cohen

9 joint publications

Dan Vogl

6 joint publications

Shambavi Richard